MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the target of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 568,283 shares, a growth of 29.4% from the January 29th total of 439,335 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average daily volume of 136,480 shares, the days-to-cover ratio is currently 4.2 days. Based on an average daily volume of 136,480 shares, the days-to-cover ratio is currently 4.2 days. Approximately 1.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after acquiring an additional 136,438 shares during the period. Two Sigma Investments LP lifted its holdings in shares of MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after purchasing an additional 25,816 shares in the last quarter. Creative Planning bought a new position in shares of MIRA Pharmaceuticals in the 2nd quarter worth $27,000. XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals in the 2nd quarter valued at $26,000. Finally, Fifth Third Bancorp bought a new stake in MIRA Pharmaceuticals during the 4th quarter valued at $30,000. 35.16% of the stock is owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Stock Down 1.6%

MIRA Pharmaceuticals stock opened at $1.22 on Thursday. The company has a market capitalization of $51.09 million, a PE ratio of -0.80 and a beta of 1.78. MIRA Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $2.45. The firm’s fifty day moving average is $1.34 and its 200 day moving average is $1.40.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MIRA shares. Rodman & Renshaw initiated coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating on the stock. Wall Street Zen cut MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.